chufangao/CTO huggingface dataset:
Clinical trial NCT01850524: IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Official title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 705.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-04-29
Primary completion date: 2019-12-02
Completion date: 2022-06-24
Baseline population: ITT population included all participants who are randomized.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT05099549: Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
Official title: A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
Sponsor: NKGen Biotech, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best options to advance this project with an allogeneic off-the-shelf NK cell product while NKGen will focus on CNS with SNK01.
Enrollment: 11.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-11-03
Primary completion date: 2023-09-21
Completion date: 2023-09-21
Clinical trial NCT05406765: Enhanced Recovery After Laparoscopic Colorectal Surgery
Official title: Spinal Analgesia for Laparoscopic Abdominoperineal Rectal Amputation Using an Enhanced Recovery After Surgery Program: a Randomized Double-blind Placebo-controlled Trial
Sponsor: University Hospital of North Norway (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-01
Primary completion date: 2022-10-07
Completion date: 2022-10-07
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04470674: Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
Official title: Randomized Phase II Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
Sponsor: Hoosier Cancer Research Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of Accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-06
Primary completion date: 2021-06-08
Completion date: 2021-06-08
Plan to share individual participant data: NO
Clinical trial NCT04337931: A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
Official title: A Phase II Multicenter, Open-label Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody Sotigalimab (APX005M) With or Without Stereotactic Body Radiation Therapy in Adults With Unresectable or Metastatic Melanoma
Sponsor: Apexigen America, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business decision (not due to safety reason).
Enrollment: 45.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-06-12
Primary completion date: 2022-07-29
Completion date: 2022-08-02
Baseline population: The Safety Population was defined as all participants who received any sotigalimab.
Plan to share individual participant data: NO
Clinical trial NCT03178864: Study of Rivaroxaban for CeREbral Venous Thrombosis
Official title: Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Early Anticoagulation With Rivaroxaban Versus Standard of Care in Determining Safety at 365 Days in Symptomatic Cerebral Venous Thrombosis
Acronym: SECRET
Sponsor: University of British Columbia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 55.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-12
Primary completion date: 2022-10-05
Completion date: 2022-10-05
Plan to share individual participant data: YES
IPD sharing description: Upon completion of the SECRET Trial, a public use database will be prepared by stripping any and all personal identifiers. The public use database, consisting of several data files, should contain: (1) baseline and demographic characteristics; (2) outcomes assessments; (3) CT/MRI data; (4) concomitant medications and procedures; and (5) adverse events. Each data file is made available as a formatted SAS dataset or other electronic format. The data files are distributed along with the data dictionary and a brief instruction (Readme) file. These data files will be made available to the public only after all major manuscripts (including secondary analysis papers) of the Trial are accepted for publication in peer-reviewed journals.
Clinical trial NCT05283954: Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea
Official title: Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression in Papua New Guinea: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Sponsor: Lihir Medical Centre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-01
Primary completion date: 2022-06-30
Completion date: 2022-07-30
Clinical trial NCT05732454: A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
Official title: A PHASE 2/3, TWO-PART STUDY TO EVALUATE THE EFFICACY AND LONG-TERM SAFETY WITH ORAL ETRASIMOD, 2 MG, ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Per the results of the planned interim analysis, the study met futility criteria for efficacy so the trial was terminated. This decision was made for efficacy reasons only and is not due to any safety concerns.
Enrollment: 58.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-01-18
Primary completion date: 2024-04-29
Completion date: 2024-04-29
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04294472: A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
Official title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients (Neutra4)
Sponsor: Vera Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-08-05
Primary completion date: 2022-02-10
Completion date: 2022-02-10
Baseline population: The Participant Flow module included 30 participants randomized; two subjects randomized but not treated were identified, leaving 28 randomized and treated subjects in subsequent modified intent-to-treat analyses. Overall Number of Baseline Participants was based on 28 randomized and treated participants.
Clinical trial NCT00089245: Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Official title: Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms
Sponsor: Y-mAbs Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Corporate business decision. No safety or efficacy concerns.
Enrollment: 177.0 (ACTUAL)
Number of arms: 1.0
Start date: 2004-02-05
Primary completion date: 2022-02-02
Completion date: 2022-02-02
Clinical trial NCT03986944: A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
Official title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.
Sponsor: ObsEva SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study halted due to the significant enrollment challenges encountered since its beginning. Screening and enrollment have been impacted by the COVID pandemic and more importantly by changes in the diagnosis and treatment of women with endometriosis.
Enrollment: 85.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-05-23
Primary completion date: 2021-01-06
Completion date: 2021-02-16
Plan to share individual participant data: NO
Clinical trial NCT03284827: Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
Official title: a Multicenter, Randomized, Open-label, Active-treatment, Controlled Trial to Compare the Efficacy of NOAC With Edoxaban vs. Dual Antiplatelet Therapy (DAPT) for Prevention of Leaflet Thrombosis (Documented by Cardiac CT Imaging) and Cerebral Embolization (Documented With Brain DW-MRI Imaging) in Patients Without an Absolute Indication for Chronic OAC After Successful TAVR
Acronym: ADAPT-TAVR
Sponsor: Asan Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 235.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-15
Primary completion date: 2021-10-26
Completion date: 2021-11-05
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03318757: Bupivacaine Liposomal Injectable Suspension, Pain and Narcotic Use After Elective Orthognathic Surgery
Official title: Does Bupivacaine Liposomal Injectable Suspension Decrease Post-operative Pain and Narcotic Use After Elective Orthognathic Surgery?
Sponsor: Boston University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: The research could not be conducted as it was denied by the IRB.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-30
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT04884295: Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19
Official title: A 2-part Clinical Study Including a First in Human, Open Label, Single Ascending Dose Part (Phase 1) Followed by a Randomised, Double Blind, Placebo-controlled Part (Phase 2) to Evaluate the Efficacy and Safety of XVR011 in Patients Hospitalised for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
Sponsor: ExeVir Bio BV (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The sponsor does not intend to start Part 2 (Phase 2) due to change in company strategy for phase 2 design. This early end of trial is not due to reasons of safety or lack of efficacy. Part 1 (Phase 1) is completed as per protocol.
Enrollment: 27.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-26
Primary completion date: 2022-03-18
Completion date: 2022-03-18
Plan to share individual participant data: NO
Clinical trial NCT04460807: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer
Official title: EXemestane in Progesterone and/or Estrogen Receptor Positive Epithelial Ovarian Cancer: A Randomized Phase III Trial, EXPERT
Acronym: EXPERT
Sponsor: Ente Ospedaliero Ospedali Galliera (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: low accrual, COVID 19 emergency and the modification of the standard of care for ovarian cancer treatment
Enrollment: 23.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-13
Primary completion date: 2023-04-27
Completion date: 2023-04-27
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in the primary publication of the trial will be shared (text, tables, figures, and appendices), after deidentification.
IPD time frame: Data will be shared 3 months following the publication of the article and they will remain available for 36 months.
IPD access criteria: the investigators who would like to use the data have to prepare a proposal that needs to be approved the Steering committee. The aim of the access to study data needs to be specified in the proposal. Proposals should be sent to the Principal investigator (andrea.decensi@galliera.it). To gain access, data requestors will need to sign a data access agreement.
Clinical trial NCT05153408: (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Official title: A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Sponsor: Blueprint Medicines Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of efficacy
Enrollment: 20.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-01-13
Primary completion date: 2022-12-09
Completion date: 2022-12-09
Plan to share individual participant data: NO
Clinical trial NCT03268902: Early Life Interventions for Childhood Growth and Development In Tanzania
Official title: Early Life Interventions for Childhood Growth and Development In Tanzania
Acronym: ELICIT
Sponsor: Haydom Lutheran Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 1188.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-09-05
Primary completion date: 2020-02-28
Completion date: 2020-03-26
Plan to share individual participant data: NO
Clinical trial NCT02728050: Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Official title: Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 84.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-12-01
Primary completion date: 2022-02-03
Completion date: 2023-04-04
Limitations and caveats: Study was limited by its single-institution and non-randomized nature
Plan to share individual participant data: NO
Clinical trial NCT03275376: Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma
Official title: Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma: A Randomized Controlled Study
Sponsor: Taichung Veterans General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow in patient enrollment
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-21
Primary completion date: 2020-12-21
Completion date: 2021-03-13
Plan to share individual participant data: NO
Clinical trial NCT04160091: Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis (RANGE)
Sponsor: Pacira Pharmaceuticals, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated prematurely due to the COVID-19 pandemic creating uncertainty impacting trial progress and costs.
Enrollment: 19.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-11-07
Primary completion date: 2020-06-15
Completion date: 2020-06-15
Limitations and caveats: This study was terminated early by the Sponsor due to the COVID-19 pandemic. Summary statistics were calculated for available data, but given that only approximately 8% of the planned study population had enrolled and there no conclusions can be drawn from this study.
Clinical trial NCT02480114: Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy
Official title: A Randomized Phase III Trial of Gabapentin Versus Standard of Care for Prevention and Treatment of Mucositis in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation
Sponsor: Vanderbilt-Ingram Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 79.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-07-31
Primary completion date: 2019-09-30
Completion date: 2020-01-31
Clinical trial NCT04567225: Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
Official title: Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Stopped after internal review
Enrollment: 39.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-01
Primary completion date: 2021-08-27
Completion date: 2021-08-27
Baseline population: Study withdrawn. The study was closed due to lack of proper resource availability. Since study could not be completed as planned, no analysis was completed.
Limitations and caveats: The study was closed due to lack of proper resource availability. Since study could not be completed as planned, no analysis was completed.
Plan to share individual participant data: NO
IPD sharing description: Individual subject results will not be shared with those involved in the prospective arm
Clinical trial NCT02384889: DFMO in Children With Type 1 Diabetes
Official title: Targeting Polyamines Using DFMO in Persons With Type 1 Diabetes: A Randomized, Double-Masked, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Initial Pharmacodynamics of Multiple Ascending Doses
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 41.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-04-30
Primary completion date: 2019-10-07
Completion date: 2020-01-06
Clinical trial NCT03292588: A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children
Official title: Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (ICAC-30)
Acronym: MUPPITS-2
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 335.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-07
Primary completion date: 2021-04-20
Completion date: 2021-04-20
Baseline population: Intent-to-treat population with available data
Plan to share individual participant data: YES
IPD sharing description: Participant level data access and additional relevant materials will be made available upon completion of the trial.
IPD time frame: After completion of the trial, within 24 months status post database lock.
IPD access criteria: Registration is available for the Immunology Database and Analysis Portal (ImmPort) at: https://www.immport.org/registration. Submit a rationale for the purpose of requesting study data access.~ImmPort is a long-term archive of clinical and mechanistic data, a National Institute of Allergy and Infectious Diseases Division of Allergy, Immunology and Transplantation (NIAID DAIT)-funded data repository. This archive is in support of the NIH mission to share data with the public. Data shared through ImmPort is provided by NIH-funded programs, other research organizations and individual scientists, ensuring these discoveries will be the foundation of future research.
Clinical trial NCT01166113: Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide
Official title: A Phase I/II, Multi-center, Open Label Study of Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma Relapsed and/or Refractory to Lenalidomide
Acronym: PCP
Sponsor: Fondazione EMN Italy Onlus (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 67.0 (ACTUAL)
Number of arms: 1.0
Start date: 2010-07-31
Primary completion date: 2011-06-30
Completion date: 2023-06-30
Clinical trial NCT03283371: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
Acronym: OPUS
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 67.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-20
Primary completion date: 2020-01-11
Completion date: 2020-11-18
Baseline population: The Intent to Treat (ITT) population is defined as all participants who were randomized and received any dose of study treatment. Ethnicity was not collected in this study.
Clinical trial NCT03838848: KN046 in Patients With Advanced Non-small Cell Lung Cancer
Official title: A Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of KN046 in Patients With Advanced Non-small Cell Lung Cancer
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Cohort A,B,C end enrollments. Cohort D and E were considered to have no significant clinical benefit at the SMC meeting and decided to terminate enrollment.
Enrollment: 120.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-05-05
Primary completion date: 2022-07-30
Completion date: 2022-07-30
Plan to share individual participant data: NO
Clinical trial NCT01950507: Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease
Official title: Evaluation of Serum Concentrations of Budesonide in Patients Treated for Gastrointestinal Graft-Versus-Host Disease and the Potential Interaction With Fluconazole or Voriconazole
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Slow/Insufficient accrual
Enrollment: 15.0 (ACTUAL)
Number of arms: 3.0
Start date: 2014-02-20
Primary completion date: 2018-05-10
Completion date: 2020-02-26